[
  {
    "ts": null,
    "headline": "Walmart CEO wants ‘everybody to make it to the other side’ and the retail giant will keep headcount flat for now even as AI changes every job",
    "summary": "But Walmart's 2.1 million-strong workforce will change in composition due to AI.",
    "url": "https://finnhub.io/api/news?id=d5d42c87eae5e45256c8704240d27a02fcb53fc5268f51075aa1df6ff84505f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759011885,
      "headline": "Walmart CEO wants ‘everybody to make it to the other side’ and the retail giant will keep headcount flat for now even as AI changes every job",
      "id": 136907489,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRM",
      "source": "Yahoo",
      "summary": "But Walmart's 2.1 million-strong workforce will change in composition due to AI.",
      "url": "https://finnhub.io/api/news?id=d5d42c87eae5e45256c8704240d27a02fcb53fc5268f51075aa1df6ff84505f0"
    }
  },
  {
    "ts": null,
    "headline": "Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions",
    "summary": "Incyte Corporation (NASDAQ:INCY) ranks among the most undervalued NASDAQ stocks to buy now. Citizens JMP reaffirmed its Market Perform rating on Incyte Corporation (NASDAQ:INCY) on September 18 after the company revealed updated clinical trial findings for its medication povorcitinib. The company evaluated povorcitinib in patients with moderate-to-severe hidradenitis suppurativa in its pivotal Phase 3 STOP-HS1/HS2 […]",
    "url": "https://finnhub.io/api/news?id=5ae6bcf3ecf08e484203067dc82e9fa81f17274cf9de838eafdce8fbbb84aeb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758949163,
      "headline": "Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions",
      "id": 136904076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRM",
      "source": "Yahoo",
      "summary": "Incyte Corporation (NASDAQ:INCY) ranks among the most undervalued NASDAQ stocks to buy now. Citizens JMP reaffirmed its Market Perform rating on Incyte Corporation (NASDAQ:INCY) on September 18 after the company revealed updated clinical trial findings for its medication povorcitinib. The company evaluated povorcitinib in patients with moderate-to-severe hidradenitis suppurativa in its pivotal Phase 3 STOP-HS1/HS2 […]",
      "url": "https://finnhub.io/api/news?id=5ae6bcf3ecf08e484203067dc82e9fa81f17274cf9de838eafdce8fbbb84aeb4"
    }
  }
]